Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF 1.1b

Cosmo Pharmaceuticals Valuation

Is COPN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COPN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 974.05
Fair Value
93.2% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: COPN (CHF66.5) is trading below our estimate of fair value (CHF974.05)

Significantly Below Fair Value: COPN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COPN?

Key metric: As COPN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COPN. This is calculated by dividing COPN's market cap by their current earnings.
What is COPN's PE Ratio?
PE Ratio19x
Earnings€59.99m
Market Cap€1.14b

Price to Earnings Ratio vs Peers

How does COPN's PE Ratio compare to its peers?

The above table shows the PE ratio for COPN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76x
DESN Dottikon ES Holding
42.7xn/aCHF 4.5b
NWRN Newron Pharmaceuticals
14.6x45.19%CHF 344.9m
SDZ Sandoz Group
130.5x29.82%CHF 23.9b
GALD Galderma Group
116.3x30.98%CHF 35.5b
COPN Cosmo Pharmaceuticals
19x35.29%CHF 1.1b

Price-To-Earnings vs Peers: COPN is good value based on its Price-To-Earnings Ratio (19x) compared to the peer average (76x).

Price to Earnings Ratio vs Industry

How does COPN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
COPN 19.0xIndustry Avg. 24.3xNo. of Companies10PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COPN is good value based on its Price-To-Earnings Ratio (19x) compared to the European Pharmaceuticals industry average (23.8x).

Price to Earnings Ratio vs Fair Ratio

What is COPN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COPN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19x
Fair PE Ratio24.5x

Price-To-Earnings vs Fair Ratio: COPN is good value based on its Price-To-Earnings Ratio (19x) compared to the estimated Fair Price-To-Earnings Ratio (24.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COPN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 65.80
CHF 98.59
+49.83%
20.67%CHF 130.12CHF 79.66n/a4
Nov ’26CHF 67.50
CHF 87.46
+29.57%
11.99%CHF 102.25CHF 79.10n/a3
Oct ’26CHF 66.10
CHF 87.82
+32.86%
11.84%CHF 102.42CHF 79.01n/a3
Sep ’26CHF 65.30
CHF 87.84
+34.52%
11.82%CHF 102.42CHF 79.01n/a3
Aug ’26CHF 58.50
CHF 98.70
+68.71%
21.55%CHF 132.09CHF 78.68n/a4
Jul ’26CHF 58.70
CHF 101.90
+73.59%
22.17%CHF 132.63CHF 79.00n/a3
Jun ’26CHF 56.90
CHF 101.76
+78.84%
22.25%CHF 132.55CHF 78.73n/a3
May ’26CHF 47.65
CHF 102.21
+114.51%
22.12%CHF 132.83CHF 78.90n/a3
Apr ’26CHF 55.60
CHF 103.52
+86.19%
22.40%CHF 135.18CHF 80.29n/a3
Mar ’26CHF 65.70
CHF 104.03
+58.34%
21.25%CHF 132.62CHF 78.77n/a3
Feb ’26CHF 65.90
CHF 98.41
+49.33%
22.14%CHF 133.03CHF 79.28n/a4
Jan ’26CHF 63.70
CHF 97.48
+53.02%
22.03%CHF 132.13CHF 79.05n/a4
Dec ’25CHF 63.20
CHF 97.48
+54.23%
22.03%CHF 132.13CHF 79.05n/a4
Nov ’25CHF 68.10
CHF 97.34
+42.93%
22.87%CHF 132.93CHF 76.59CHF 67.504
Oct ’25CHF 74.90
CHF 97.13
+29.68%
23.05%CHF 132.99CHF 76.32CHF 66.104
Sep ’25CHF 79.90
CHF 97.38
+21.87%
22.85%CHF 132.96CHF 76.63CHF 65.304
Aug ’25CHF 74.60
CHF 97.38
+30.53%
22.85%CHF 132.96CHF 76.63CHF 58.504
Jul ’25CHF 70.80
CHF 93.19
+31.62%
15.18%CHF 112.82CHF 78.44CHF 58.704
Jun ’25CHF 70.80
CHF 93.09
+31.48%
13.45%CHF 109.09CHF 79.54CHF 56.904
May ’25CHF 72.30
CHF 93.09
+28.75%
13.45%CHF 109.09CHF 79.54CHF 47.654
Apr ’25CHF 71.30
CHF 93.00
+30.43%
13.68%CHF 109.38CHF 79.27CHF 55.604
Mar ’25CHF 67.10
CHF 75.96
+13.21%
9.98%CHF 83.49CHF 65.58CHF 65.703
Feb ’25CHF 62.20
CHF 75.96
+22.13%
9.98%CHF 83.49CHF 65.58CHF 65.903
Jan ’25CHF 50.90
CHF 73.12
+43.66%
11.28%CHF 84.75CHF 66.58CHF 63.703
Dec ’24CHF 42.75
CHF 73.36
+71.60%
10.65%CHF 84.41CHF 67.77CHF 63.203
Nov ’24CHF 35.20
CHF 73.97
+110.14%
10.63%CHF 85.09CHF 68.37CHF 68.103
CHF 98.59
Fair Value
32.5% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/24 16:47
End of Day Share Price 2025/11/24 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura HindleyBerenberg
Kerry HolfordBerenberg
Julie SimmondsCanaccord Genuity